A 5-year global open-label extension study found that early treatment with the RNA interference therapeutic patisiran for hereditary transthyretin amyloidosis with polyneuropathy led to better clinical stability and survival. The trial enrolled 211 patients across 19 countries and showed that patients exhibited a survival advantage and reduced disease progression when initiating treatment earlier.